hotspot -WSS

hotspot

author：comprehensive 2025-09-29 00:39:14 - browse：9

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Illumina to lay off 10% of research and development team

WSS

Brazil's Jair Bolsonaro is barred from running for office until 2030

Crowdfunding for unproven stem cell procedures spreads misinformation

ADA: All diabetes patients should be screened for liver condition

Synthetic human embryos? Researchers say term is overblown

GOP inquiry over gain

Eating disorder hotline's move to chatbot carried cost for volunteers

hotspot

hotspot

hotspot

Medicare details structure of new drug price negotiation program

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Virginia high school admissions case could be legal follow

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Virginia high school admissions case could be legal follow

Tuskegee Airman Raymond Cassagnol dies at 102

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Canadians with cystic fibrosis outlive Americans by a decade

In Memoriam: Notable people who died in 2023

The simple reason for the increase in autism diagnosis

focus

The strange history of BMI, the body mass index

Crowdfunding for unproven stem cell procedures spreads misinformation

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

The simple reason for the increase in autism diagnosis

Medical experts exlpore how to eliminate bias in clinical algorithms

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

hotspot

knowledge

hotspot

focus